Efficacy of Intrapleural or Intrapericardial Injection of Single Bevacizumab in the Treatment of Lung Cancer-Mediated Malignant Effusion

Table 1

Patient characteristics.

Characteristics	Local injection site
	Intrapleural (%)	Intrapericardial (%)
Age (years)	n = 14	n = 8
<65	6 (42.9)	0
≥65	8 (57.1)	8 (100)
Sex	n = 14	n = 8
Male	9 (64.3)	5 (62.5)
Female	5 (35.7)	3 (37.5)
Pathology	n = 14	n = 8
Adenocarcinoma	14 (100)	6 (75)
Squamous	0	2 (25)
Lines of treatment	n = 14	n = 8
First-line	1 (7.1)	1 (12.5)
Non-first-line	13 (92.9)	7 (87.5)
LCSS (mean ± SD)	n = 14	n = 8
Before treatment (days)	127 ± 41	91 ± 12
After treatment (days)
PS (mean ± SD)	n = 14	n = 8
Before treatment	2.5 ± 0.65	3 ± 0.93
After treatment	1.3 ± 0.91	1.4 ± 0.92
Adverse effect	n = 14	n = 8
Dizzy	1 (7.1)	0